Aminoguanidine indole derivative as well as preparation method and application thereof

By developing aminoguanidine indole derivatives, the problem of resistance to commonly used antibiotics of Klebsiella pneumoniae was solved, and effective inhibition and killing of the bacteria was achieved, especially in drug-resistant strains, A new treatment option is provided.

CN119080667AActive Publication Date: 2024-12-06LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410577889.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-10
Publication Date
2024-12-06
Estimated Expiration
2044-05-10

AI Technical Summary

Technical Problem

Klebsiella pneumoniae is resistant to commonly used antibiotics, resulting in increased infectivity and treatment difficulty, and new anti-Klebsiella pneumoniae drugs need to be developed.

Method used

Develop an aminoguanidine indole derivative, prepared by reacting with 5-indole formaldehyde under alkaline and acidic conditions, and has the effect of inhibiting Klebsiella pneumoniae, and is used to prevent and treat diseases caused by Klebsiella pneumoniae .

Benefits of technology

Aminoguanidine indole derivatives have an inhibitory and killing effect on Klebsiella pneumoniae, effectively preventing and treating diseases caused by Klebsiella pneumoniae, especially showing excellent inhibitory and bactericidal effects on drug-resistant strains.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080667A_ABST
    Figure CN119080667A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicine synthesis, in particular to an aminoguanidine indole derivative as well as a preparation method and application thereof. The invention relates to an aminoguanidine indole derivative, which has the following structural general formula: # imgabs0 #, and in the formula, R1-R5 are respectively and independently H, halogen atom, trifluoromethyl or cyano group. The aminoguanidine indole derivative is applied to inhibition or killing of klebsiella pneumoniae. The aminoguanidine indole derivative is applied to preparation of drugs for preventing and treating diseases caused by klebsiella pneumoniae infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of drug synthesis, in particular to an aminoguanidine indole derivative and a preparation method and application thereof. Background Art

[0002] Klebsiella pneumoniae is a bipolar, Gram-negative, thick, short rod that is anaerobic, non-motile, flagella, and spore-bearing. Most strains have pili and capsules. Klebsiella pneumoniae can cause a variety of infections or diseases, including pneumonia, urinary tract infections, bacteremia, and liver abscesses. Klebsiella pneumoniae mainly causes severe infections in immunocompromised individuals, but the emergence and spread of highly virulent strains make it possible for people with healthy immune functions to be infected. Klebsiella pneumoniae has virulence factors such as capsules, LPS, pili, and siderophores, which can effectively resist the killing of the immune system and help it colonize, and highly virulent strains have capsules with a highly sticky phenotype.

[0003] Klebsiella pneumoniae is an important conditional pathogen that can infect humans and a variety of animals and is widely present in the natural environment and organisms. Klebsiella pneumoniae often colonizes various biological and non-biological surfaces, including the upper respiratory tract and intestines. The colonization rate varies greatly between individuals depending on their habitat and exposure. When Klebsiella pneumoniae is detected in the patient's blood, accompanied by symptoms such as fever, cough, sputum, leukocytosis and pneumonia, Klebsiella pneumoniae infection is considered. The colonization rate of Klebsiella pneumoniae ranges from 18.8% to 87.7% in Asia and 5% to 35% in Western countries. Among hospitalized patients, the colonization rate in the nasopharynx is as high as 19%, while the colonization rate in the gastrointestinal tract can be as high as 77%. Colonized Klebsiella pneumoniae can cause infection when the body's immunity is low. Klebsiella pneumoniae colonized in the gastrointestinal tract is the main source of hospital Klebsiella pneumoniae infection, 80% of which are caused by self-colonization strains.

[0004] Klebsiella pneumoniae is one of the "ESKAPE" pathogens (including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) that are considered a serious threat by the Centers for Disease Control and Prevention in the United States. Its drug resistance is relatively serious. The "2022 National Bacterial Drug Resistance Monitoring Report (Brief Version)" pointed out that drug-resistant Klebsiella pneumoniae ranks second in the isolation rate of Gram-negative drug-resistant bacteria, second only to Escherichia coli. Klebsiella pneumoniae shows a certain degree of resistance to commonly used antibiotics and can acquire resistance through a variety of pathways. It has natural resistance to penicillin, with a national average resistance rate to third-generation cephalosporins of 29.8%, a national average resistance rate to carbapenems of 11.3%, and a resistance rate to levofloxacin and gentamicin of nearly 20%.

[0005] Therefore, it is necessary to find new anti-Klebsiella pneumoniae drugs. Summary of the invention

[0006] The purpose of the present invention is to provide an aminoguanidine indole derivative, which has an inhibitory and killing effect on Klebsiella pneumoniae and can be used for preventing and treating diseases caused by Klebsiella pneumoniae infection.

[0007] To achieve the above object, the present invention provides the following technical solutions:

[0008] An aminoguanidine indole derivative has the following general structural formula:

[0009]

[0010] Wherein, R1 to R5 are each independently H, a halogen atom, a trifluoromethyl group or a cyano group.

[0011] Preferably, at least one of R1 to R5 is a halogen atom, a trifluoromethyl group or a cyano group.

[0012] Preferably, 1-2 of the R1 to R5 are halogen atoms or trifluoromethyl groups, and the remaining values ​​are H. Preferably, the halogen is F, Cl or Br.

[0013] Preferably, the aminoguanidine indole derivative is:

[0014] (E)-2-((1-(2-fluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0015] (E)-2-((1-(3-fluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0016] (E)-2-((1-(4-fluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0017] (E)-2-((1-(2,4-difluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0018] (E)-2-((1-(2,5-difluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0019] (E)-2-((1-(2,6-difluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0020] (E)-2-((1-(3,5-difluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0021] (E)-2-((1-(3,4-difluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0022] (E)-2-((1-(3-(trifluoromethyl)benzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0023] (E)-2-((1-(4-(trifluoromethyl)benzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0024] (E)-2-((1-(3,5-bis(trifluoromethyl)benzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0025] (E)-2-((1-(2-chlorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0026] (E)-2-((1-(3-chlorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0027] (E)-2-((1-(4-chlorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0028] (E)-2-((1-(2,4-dichlorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0029] (E)-2-((1-(3,4-dichlorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0030] (E)-2-((1-(2-bromobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0031] (E)-2-((1-(3-bromobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0032] (E)-2-((1-(4-bromobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0033] (E)-2-((1-(2-chloro-4-fluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0034] (E)-2-((1-(3-chloro-4-fluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine;

[0035] (E)-2-((1-(4-cyanobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine.

[0036] More preferably, the aminoguanidine indole derivative is:

[0037] (E)-2-((1-(3,4-dichlorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine.

[0038] A method for preparing the above-mentioned aminoguanidine indole derivative comprises the following steps:

[0039] Step 1: Under alkaline conditions, Reaction with 5-indolecarboxaldehyde to obtain

[0040] Step 2: Under acidic conditions, and The reaction yields the aminoguanidine indole derivative.

[0041] Preferably, in step 1, the base is potassium hydroxide.

[0042] Preferably, in step 2, the acid is concentrated hydrochloric acid.

[0043] Application of the above aminoguanidine indole derivatives in inhibiting or killing Klebsiella pneumoniae.

[0044] The aminoguanidine indole derivative is used in the preparation of medicines for preventing and treating diseases caused by Klebsiella pneumoniae infection.

[0045] The diseases are pneumonia, urinary tract infection, bacteremia, liver abscess or infection at other sites caused by Klebsiella pneumoniae in humans and animals.

[0046] The beneficial effect of the present invention is that the compound prepared by the present invention has an inhibitory and killing effect on Klebsiella pneumoniae and can be used to prevent and treat diseases caused by Klebsiella pneumoniae infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 The growth curves of KP2108 under different treatments in Example 5 of the present invention;

[0048] Figure 2 This is the time-kill curve of 3P against KP2108 in Example 6 of the present invention;

[0049] Figure 3 This is the effect of 3P on the survival rate of mice with Klebsiella pneumoniae pneumonia in Example 7 of the present invention (survival curve). DETAILED DESCRIPTION

[0050] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0051] Example 1

[0052] Preparation of (E)-2-((1-(4-chlorobenzyl)-1H-indole-5-)methylene)hydrazino-1-amidine

[0053] Synthesis of 1-(4-chlorobenzyl)-1H-indole-5-carboxaldehyde: 1009 mg (18 mmol) of potassium hydroxide was added to 20 mL of N,N-dimethylformamide, and stirred at room temperature for 5 minutes. Then, 871 mg (6 mmol) of 5-indolecarboxaldehyde was added. After stirring at room temperature for 45 minutes, 1234 mg (6 mmol) of 4-chlorobenzyl bromide was added. After stirring at room temperature for 3 hours, the reaction solution was poured into 70 mL of ice water and extracted with ethyl acetate. The extract was washed twice with saturated brine, and then dehydrated with anhydrous sodium sulfate. After removing ethyl acetate by vacuum distillation, a yellow-brown solid was obtained. The white crystals (1442 mg) were recrystallized in ethanol. The yield was 89%.

[0054] Synthesis of (E)-2-((1-(4-chlorobenzyl)-1H-indole-5-)methylene)hydrazine-1-amidine: 269 mg (1 mmol) of 1-(4-bromobenzyl)-1H-indole-5-carbaldehyde and 110 mg (1 mmol) of aminoguanidine hydrochloride were stirred in 15 mL of anhydrous ethanol, 20 drops of concentrated hydrochloric acid and 3 mL of water were added, and the reaction was stirred in an oil bath at 50°C for 2-6 hours. The reaction was purified by column chromatography using dichloromethane:methanol = 15:1 to 10:1 to obtain 229 mg of a white solid with a yield of 70%.

[0055] Example 2

[0056] Preparation of (E)-2-((1-(3,4-dichlorobenzyl)-1H-indole-5-)methylene)hydrazino-1-amidine

[0057] Synthesis of 1-(3,4-dichlorobenzyl)-1H-indole-5-carboxaldehyde: Add 1122 mg (20 mmol) of potassium hydroxide to 20 mL of N,N-dimethylformamide, stir at room temperature for 5 minutes, add 726 mg (5 mmol) of 5-indolecarboxaldehyde, stir at room temperature for 45 minutes, add 1200 mg (5 mmol) of 3,4-dichlorobenzyl bromide, stir at room temperature for 45 minutes, pour the reaction solution into 70 mL of ice water, extract with ethyl acetate, wash the extract twice with saturated brine, remove water with anhydrous sodium sulfate, and remove ethyl acetate under reduced pressure to obtain a yellow liquid.

[0058] Synthesis of (E)-2-((1-(3,4-dichlorobenzyl)-1H-indole-5-)methylene)hydrazine-1-amidine: All the obtained 1-(3,4-dichlorobenzyl)-1H-indole-5-carboxaldehyde and 608 mg (5.5 mmol) of aminoguanidine hydrochloride were stirred in 20 mL of anhydrous ethanol, and 20 drops of concentrated hydrochloric acid and 4 mL of water were added. The reaction was stirred in an oil bath at 50°C for 2 hours and then stopped. The mixture was purified by column chromatography using dichloromethane:methanol = 15:1 to 10:1 to obtain 566 mg of a light red solid with a yield of 31%.

[0059] Example 3

[0060] Preparation of (E)-2-((1-(4-bromobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine

[0061] Synthesis of 1-(4-bromobenzyl)-1H-indole-5-carboxaldehyde: 1009 mg (18 mmol) of potassium hydroxide was added to 20 mL of N,N-dimethylformamide, and stirred at room temperature for 5 minutes. Then, 871 mg (6 mmol) of 5-indolecarboxaldehyde was added. After stirring at room temperature for 45 minutes, 1500 mg (6 mmol) of 4-bromobenzyl bromide was added. After stirring at room temperature for 45 minutes, the reaction solution was poured into 70 mL of ice water and extracted with ethyl acetate. The extract was washed twice with saturated brine, and then dehydrated with anhydrous sodium sulfate. After removing ethyl acetate by distillation under reduced pressure, a yellow-brown solid was obtained. The white crystals (479 mg) were recrystallized in ethanol with a yield of 25%.

[0062] Synthesis of (E)-2-((1-(4-bromobenzyl)-1H-indole-5-)methylene)hydrazine-1-amidine: 314 mg (1 mmol) of 1-(4-bromobenzyl)-1H-indole-5-carbaldehyde and 111 mg (1 mmol) of aminoguanidine hydrochloride were dissolved in 15 mL of anhydrous ethanol, 20 drops of concentrated hydrochloric acid and 3 mL of water were added, and the reaction was stirred in an oil bath at 50°C for 2-6 hours. The reaction was purified by column chromatography using dichloromethane:methanol = 15:1 to 10:1 to obtain 139 mg of a white solid with a yield of 37.5%.

[0063] A series of aminoguanidine indole derivatives were prepared by the above-mentioned synthesis method. The structural formula, molecular formula and chemical name of each compound are shown in Table 1, and the corresponding hydrogen nuclear magnetic resonance spectrum, carbon nuclear magnetic resonance spectrum and high-resolution mass spectrum data are shown in Table 2.

[0064] Table 1: Structures, molecular formulas and corresponding chemical names of aminoguanidine indole derivatives

[0065]

[0066]

[0067]

[0068]

[0069]

[0070] Table 2: H NMR, C NMR and high resolution mass spectrometry data of aminoguanidine indole derivatives

[0071]

[0072]

[0073]

[0074]

[0075]

[0076]

[0077] Example 4: Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) test of aminoguanidine indole derivatives

[0078] The minimum inhibitory concentration and minimum bactericidal concentration of Klebsiella pneumoniae (ATCC 700603) and clinical drug-resistant strains of Klebsiella pneumoniae (KP2108, KP2105, KP2109, KP2135, KP2138) were determined by the microbroth dilution method. Compounds 3A-3V were prepared into 2560 μg / mL DMSO solution, 10 μL of compound solution was mixed with 190 μL MH broth in a 96-well plate, 100 μL of the mixture was diluted two-fold in a 96-well plate, 100 μL of the 100-fold diluted bacterial solution was inoculated, and the mixture was cultured at 37°C for 16-20 hours. The clarity of the mixture was observed by naked eyes, and the lowest concentration that was clear and had no bacterial precipitation at the bottom of the well was the minimum inhibitory concentration of the compound. 100 μL of the bacterial solution without bacterial growth was evenly spread on MH agar medium. After culturing at 37°C for 24 hours, the concentration at which no bacterial growth was observed was the minimum bactericidal concentration of the compound. MH broth without the compound was used as a blank control group, levofloxacin and polymyxin were used as positive control drugs, and only compounds 3I-3U were tested for clinical resistant strains of Klebsiella pneumoniae (KP2108, KP2105, KP2109, KP2135, KP2138). The minimum inhibitory concentration results are shown in Table 3, and the minimum bactericidal concentration results are shown in Table 4.

[0079] Table 3: Minimum inhibitory concentration (MIC) of aminoguanidine indole derivatives against 6 strains of Klebsiella pneumoniae

[0080]

[0081]

[0082] Table 4: Minimum bactericidal concentration (MBC) of aminoguanidine indole derivatives against 6 strains of Klebsiella pneumoniae

[0083]

[0084]

[0085] As can be seen from Table 3, the aminoguanidine indole derivatives prepared by the present invention, compounds 3I-3U, have a strong inhibitory effect on Klebsiella pneumoniae, and still show a strong inhibitory effect on clinical resistant strains of Klebsiella pneumoniae resistant to levofloxacin or polymyxin. Among them, the minimum inhibitory concentrations of 3J, 3K, 3N, 3O, 3P, 3Q, and 3T to ATCC 700603 are close to that of the control drug polymyxin, and the minimum inhibitory concentrations of 3P and 3O to some clinical resistant strains of Klebsiella pneumoniae can reach 4 μg / mL, and the antibacterial activity is excellent.

[0086] As shown in Tables 3 and 4, the minimum bactericidal concentration (MBC) of most of the tested compounds against Klebsiella pneumoniae is 1-4 times the minimum inhibitory concentration (MIC), indicating that most of the tested compounds have bactericidal activity, among which 3P exhibits excellent antibacterial and bactericidal effects.

[0087] Example 5: Effect of 3P on the growth curve of KP2108

[0088] The clinical drug-resistant strain of Klebsiella pneumoniae KP2108 was cultured in MH broth medium until the logarithmic growth phase and then diluted to 1×10 6 CFU / mL. Different concentrations of compound 3P (final concentrations of 2, 4, 8, 16 μg / mL) and control drug polymyxin (final concentration of 32 μg / mL) were added to TSB medium, and then the same volume of bacterial solution was added. The blank medium without bacterial solution was used as the negative control, and the medium without compound but with bacterial solution was used as the positive control. The culture was shaken at 37°C. The optical density value at 600nm was detected at the specified time intervals (0, 1, 2, 3, 4, 6, 8, 10, 12, 24h), and the bacterial growth curve was drawn with the optical density value at 600nm as the ordinate and time as the abscissa, as shown in the figure. Figure 1 .

[0089] Depend on Figure 1 It can be seen that the control drug polymyxin (32 μg / mL) cannot completely inhibit the growth of KP2108; when the 3P concentration is greater than or equal to 4 μg / mL, that is, greater than or equal to MIC, the growth of KP2108 is completely inhibited; when the 3P concentration is 2 μg / mL, that is, less than MIC, it cannot inhibit bacterial growth.

[0090] Example 6: Bactericidal kinetics test of 3P

[0091] The time-killing curve of different concentrations of 3P against the clinical drug-resistant strain KP2108 of Klebsiella pneumoniae was drawn. The clinical drug-resistant strain KP2108 of Klebsiella pneumoniae was cultured in MH broth medium to the logarithmic growth phase and then diluted to 1×10 7CFU / mL of bacterial suspension. Compound 3P (final concentrations of 4, 8, 16, and 32 μg / mL, respectively) and polymyxin (final concentration of 32 μg / mL) were added to the bacterial suspension and cultured at 37°C with shaking. After the specified time intervals (0, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h), 100 μL of the culture solution was taken and diluted 10 times in 0.9% saline. 100 μL of the culture solution was spread on MH agar medium for each dilution. After culturing at 37°C for 24 h, the number of colonies was counted and the number of bacteria in the culture solution was calculated. The time-killing curve was drawn with the logarithm of the number of bacteria per milliliter as the ordinate and the culture time as the abscissa. Figure 2 .

[0092] Depend on Figure 2 It can be seen that the 24h bacterial count in the polymyxin (32μg / mL) group was close to that in the blank control group, and there was no antibacterial effect. The bactericidal effect of 3P on KP2108 was concentration-dependent. Different concentrations of 3P (4, 8, 16, 32μg / mL, i.e., 1×MIC, 2×MIC, 4×MIC, 8×MIC) had significant inhibitory or killing effects on KP2108, among which the 24h bacterial count of 1×MIC was greater than the inoculation amount and less than the blank control group, which had an inhibitory effect; the 24h bacterial count of 2×MIC was less than the inoculation amount, which had a bactericidal effect; 4×MIC and 8×MIC had no bacteria surviving at 6h, which had a very significant bactericidal effect.

[0093] Example 7: In vivo antibacterial activity test of compound 3P

[0094] The effects of 3P and the control drug polymyxin on the survival rate of mice with Klebsiella pneumoniae pneumonia were measured to evaluate their in vivo efficacy. The specific process was as follows: After one week of adaptive feeding of the purchased SPF-grade BALB / c female mice, the mice were completely randomly divided into 4 groups (blank control group, model group, polymyxin group and 3P group), with 6 mice in each group, weighing 20±2g, and each group of mice was given the same food and water to eat freely. Each group of mice was given different intervention measures, among which the blank control group was not given any intervention; the model group, polymyxin group and 3P group were given Klebsiella pneumoniae cultured in MH broth medium through the nasal cavity to create a Klebsiella pneumoniae pneumonia model, and then different intervention measures were given by intraperitoneal injection, among which the model group was injected with blank solvent every day, the polymyxin group was given polymyxin solution (1mg / Kg) every day, and the 3P group was injected with 3P solution (4mg / Kg) every day. The experimental results are as follows Figure 3 .

[0095] Depend on Figure 3It can be seen that 2 days after the mice were infected, the mortality rate of the mice in the model group was 100%; after the mice were treated with 3P and polymyxin, the survival rate was significantly improved, and the survival rate of the 3P treatment group was 10% higher than that of polymyxin, indicating that the anti-Klebsiella pneumoniae activity of 3P is better than that of polymyxin in BALB / c mice.

[0096] The embodiments of the present application are described above in conjunction with the accompanying drawings, but the present application is not limited to the above-mentioned specific implementation methods. The above-mentioned specific implementation methods are merely illustrative and not restrictive. Under the guidance of the present application, ordinary technicians in this field can also make many forms without departing from the purpose of the present application and the scope of protection of the claims, all of which are within the protection of the present application.

Claims

1. An aminoguanidine indole derivative having the following general structural formula: in, R1 to R5 are each independently H, a halogen atom, a trifluoromethyl group or a cyano group.

2. An aminoguanidine indole derivative according to claim 1, characterized in that: At least one of R1 to R5 is a halogen atom, a trifluoromethyl group or a cyano group.

3. An aminoguanidine indole derivative according to claim 2, characterized in that: Among the R1 to R5, 1-2 are halogen atoms or trifluoromethyl groups, and the remaining ones are H.

4. Any one of the aminoguanidine indole derivatives according to claim 3, characterized in that: The halogen is F, Cl or Br.

5. An aminoguanidine indole derivative according to claim 4, characterized in that: The aminoguanidine indole derivative is: (E)-2-((1-(2-fluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(3-fluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(4-fluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(2,4-difluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(2,5-difluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(2,6-difluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(3,5-difluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(3,4-difluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(3-(trifluoromethyl)benzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(4-(trifluoromethyl)benzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(3,5-bis(trifluoromethyl)benzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(2-chlorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(3-chlorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(4-chlorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(2,4-dichlorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(3,4-dichlorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(2-bromobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(3-bromobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(4-bromobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(2-chloro-4-fluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(3-chloro-4-fluorobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine; (E)-2-((1-(4-cyanobenzyl)-1H-indol-5-)methylene)hydrazino-1-amidine.

6. An aminoguanidine indole derivative according to claim 5, characterized in that: The aminoguanidine indole derivative is: (E)-2-((1-(3,4-dichlorobenzyl)-1H-indole-5-)methylene)hydrazine-1-amidine.

7. A method for preparing any one of the aminoguanidine indole derivatives according to claims 1 to 6, comprising the following steps: Step 1: Under alkaline conditions, Reaction with 5-indolecarboxaldehyde to obtain Step 2: Under acidic conditions, and The reaction yields the aminoguanidine indole derivative.

8. A method for preparing an aminoguanidine indole derivative according to claim 7, characterized in that: In step 1, the base is potassium hydroxide; in step 2, the acid is concentrated hydrochloric acid.

9. Use of any one of the aminoguanidine indole derivatives according to claims 1 to 6 in inhibiting or killing Klebsiella pneumoniae.

10. Use of any one of the aminoguanidine indole derivatives according to claims 1 to 6 in the preparation of a medicament for preventing and treating a disease caused by Klebsiella pneumoniae infection; the disease is pneumonia, urinary tract infection, bacteremia, liver abscess or other infection caused by Klebsiella pneumoniae in humans and animals.

Citation Information

Patent Citations

  • Indole compounds and preparation method and application thereof as drug-resistant bacteria resistant drugs

    CN105669519A

  • Preparation method of carbazole derivatives containing triazine or aminoguanidine structure and antibacterial application of carbazole derivatives

    CN107325080A

  • N-benzenesulfonyl-indol-alkylene-aminoguanidine antibacterial compound and preparation method thereof

    CN107522650A